Literature DB >> 18640149

Desipramine blocks alcohol-induced anxiety- and depressive-like behaviors in two rat strains.

Bruk Getachew1, Sheketha R Hauser, Robert E Taylor, Yousef Tizabi.   

Abstract

Epidemiological studies indicate significant co-morbid expression of alcoholism, anxiety, and depression. These symptoms are often under-diagnosed and under-treated and can worsen prognostic and treatment outcome for alcoholism. Nonetheless, a causal relationship between alcoholism and these conditions is yet to be established. In this study we sought to determine the effects of daily alcohol administration on the indices of anxiety and depression in two rat strains, one of which exhibits inherent depressive-like characteristics. Moreover, it was of relevance to examine the effects of a clinically useful antidepressant on alcohol-induced behavioral changes. Wistar-Kyoto (WKY) rats derived from Wistar stock show low levels of locomotor activity in an open field and high levels of immobility in the forced swim test (FST) which is considered a measure of their helplessness and hence are considered a putative animal model of depression. Adult female WKY and Wistar rats were exposed for 3 hrs daily to 95% ethanol vapor to achieve a mean blood alcohol level (BAL) of approximately 150 mg/dL. Controls were exposed to air in similar inhalation chambers. Sixteen to 18 hrs following 7 or 14 days of exposure to alcohol, locomotor activity (LCA) in open field, duration of time spent in the open arm of the elevated plus-maze (EPM), reflective of anxiety-like behavior and immobility in FST were evaluated. Alcohol exposure for 7 or 14 days reduced LCA only in Wistar rats but enhanced FST immobility in both strains at both time points. Only 14 day alcohol exposure reduced EPM open arm time in both WKY and Wistar rats. Daily treatment with desipramine (8 mg/kg) blocked all the changes induced by alcohol in both strains. Thus, subchronic (7 day) exposure to alcohol induces depressive-like characteristics in Wistar rats and exacerbates that of WKY rats. Chronic (14 day) exposure, however, also induces an anxiety-like effect in both strains. The depressive- and anxiety-like behaviors induced by alcohol were blocked by daily treatment with a tricyclic antidepressant. It may be suggested that prophylactic treatment of alcoholics with an antidepressant prior to detoxification may improve treatment outcome for alcoholism.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18640149      PMCID: PMC3197815          DOI: 10.1016/j.pbb.2008.06.016

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  49 in total

1.  Prediction of resumption of drinking in posttreatment alcoholics.

Authors:  S W Glenn; O A Parsons
Journal:  Int J Addict       Date:  1991-02

2.  The course of anxiety, depression and drinking behaviours after completed detoxification in alcoholics with and without comorbid anxiety and depressive disorders.

Authors:  M Driessen; S Meier; A Hill; T Wetterling; W Lange; K Junghanns
Journal:  Alcohol Alcohol       Date:  2001 May-Jun       Impact factor: 2.826

Review 3.  The influence of alcohol drinking and alcohol use disorders on psychiatric disorders and suicidal behavior.

Authors:  M Berglund; A Ojehagen
Journal:  Alcohol Clin Exp Res       Date:  1998-10       Impact factor: 3.455

4.  Microinjection of a corticotropin-releasing factor antagonist into the central nucleus of the amygdala reverses anxiogenic-like effects of ethanol withdrawal.

Authors:  S Rassnick; S C Heinrichs; K T Britton; G F Koob
Journal:  Brain Res       Date:  1993-03-05       Impact factor: 3.252

Review 5.  Comorbidity for alcoholism and depression.

Authors:  K R Merikangas; C S Gelernter
Journal:  Psychiatr Clin North Am       Date:  1990-12

6.  Quality of life, depression and anxiety in alcohol dependence.

Authors:  Omer Saatcioglu; Aslihan Yapici; Duran Cakmak
Journal:  Drug Alcohol Rev       Date:  2008-01

7.  The relationship between DSM-IV alcohol use disorders and DSM-IV major depression: examination of the primary-secondary distinction in a general population sample.

Authors:  B F Grant; D S Hasin; D A Dawson
Journal:  J Affect Disord       Date:  1996-06-05       Impact factor: 4.839

8.  Alcohol use disorders comorbid with anxiety, depression and drug use disorders. Findings from the Australian National Survey of Mental Health and Well Being.

Authors:  Lucy Burns; Maree Teesson
Journal:  Drug Alcohol Depend       Date:  2002-12-01       Impact factor: 4.492

9.  Characteristics of suicide attempts preceded by alcohol consumption.

Authors:  Michel Lejoyeux; Françoise Huet; Micheline Claudon; Anika Fichelle; Enrique Casalino; Valérie Lequen
Journal:  Arch Suicide Res       Date:  2008

10.  The comorbidity of alcoholism with anxiety and depressive disorders in four geographic communities.

Authors:  J D Swendsen; K R Merikangas; G J Canino; R C Kessler; M Rubio-Stipec; J Angst
Journal:  Compr Psychiatry       Date:  1998 Jul-Aug       Impact factor: 3.735

View more
  20 in total

1.  Alcohol induced depressive-like behavior is associated with a reduction in hippocampal BDNF.

Authors:  Sheketha R Hauser; Bruk Getachew; Robert E Taylor; Yousef Tizabi
Journal:  Pharmacol Biochem Behav       Date:  2011-09-10       Impact factor: 3.533

2.  Effects of withdrawal from chronic intermittent ethanol vapor on the level and circadian periodicity of running-wheel activity in C57BL/6J and C3H/HeJ mice.

Authors:  Ryan W Logan; Walter D McCulley; Joseph A Seggio; Alan M Rosenwasser
Journal:  Alcohol Clin Exp Res       Date:  2011-10-20       Impact factor: 3.455

3.  Chronic alcohol exposure differentially affects activation of female locus coeruleus neurons and the subcellular distribution of corticotropin releasing factor receptors.

Authors:  T A Retson; B A Reyes; E J Van Bockstaele
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2014-08-20       Impact factor: 5.067

Review 4.  Neuroinflammation, neurodegeneration, and depression.

Authors:  Laura L Hurley; Yousef Tizabi
Journal:  Neurotox Res       Date:  2012-08-16       Impact factor: 3.911

5.  Antidepressant effects of resveratrol in an animal model of depression.

Authors:  Laura L Hurley; Luli Akinfiresoye; Olubukola Kalejaiye; Yousef Tizabi
Journal:  Behav Brain Res       Date:  2014-04-06       Impact factor: 3.332

6.  The effect of intermittent alcohol vapor or pulsatile heroin on somatic and negative affective indices during spontaneous withdrawal in Wistar rats.

Authors:  Angela M Williams; Daniel J Reis; Alexa S Powell; Louis J Neira; Kathryn A Nealey; Cole E Ziegler; Nina D Kloss; Jessica L Bilimoria; Chelsea E Smith; Brendan M Walker
Journal:  Psychopharmacology (Berl)       Date:  2012-03-31       Impact factor: 4.530

7.  Alcohol-induced depressive-like behavior is associated with cortical norepinephrine reduction.

Authors:  Bruk Getachew; Sheketha R Hauser; Robert E Taylor; Yousef Tizabi
Journal:  Pharmacol Biochem Behav       Date:  2010-06-30       Impact factor: 3.533

8.  Antidepressant-like effects of low ketamine dose is associated with increased hippocampal AMPA/NMDA receptor density ratio in female Wistar-Kyoto rats.

Authors:  Y Tizabi; B H Bhatti; K F Manaye; J R Das; L Akinfiresoye
Journal:  Neuroscience       Date:  2012-04-19       Impact factor: 3.590

9.  Hippocampal neural progenitor cells play a distinct role in fear memory retrieval in male and female CIE rats.

Authors:  McKenzie J Fannon; Karthik K Mysore; Jefferson Williams; Leon W Quach; Dvijen C Purohit; Britta D Sibley; Janna S Sage-Sepulveda; Khush M Kharidia; Roberto J Morales Silva; Michael J Terranova; Sucharita S Somkuwar; Miranda C Staples; Chitra D Mandyam
Journal:  Neuropharmacology       Date:  2018-09-28       Impact factor: 5.250

10.  Antidepressant-like effects of nicotine and reduced nicotinic receptor binding in the Fawn-Hooded rat, an animal model of co-morbid depression and alcoholism.

Authors:  Yousef Tizabi; Bruk Getachew; Amir H Rezvani; Sheketha R Hauser; David H Overstreet
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2008-09-19       Impact factor: 5.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.